Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 177-184

  Xie, Ruifan ^a   Yang, Hai ^a   Xiao, Qungen ^a   Mao, Feng ^a   Zhang, Suojun ^a   Ye, Fei ^a   Wan, Feng ^a   Wang, Baofeng ^a   Lei, Ting ^a   Guo, Dongsheng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Epidermal growth factor receptor; Glioma; Invasion; Leucine rich repeats and immunoglobulin like domains 1; Proliferation; RNA interference

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MYC PROTEIN; PROTEIN KINASE B; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; LRIG1 GENE; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; IMMUNOPRECIPITATION; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84872840197     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2102     Document Type: Article

References (35)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
2. Wang B, Han L, Chen R, et al: Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther 8: 1018-1023, 2009.
3. Guo D, Holmlund C, Henriksson R and Hedman H: The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 84: 157-165, 2004.
4. Nilsson J, Vallbo C, Guo D, et al: Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 284: 1155-1161, 2001.
5. Ishii H and Furukawa Y: Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol 79: 238-242, 2004.
6. Martinez A, Walker RA, Shaw JA, Dearing SJ, Maher ER and Latif F: Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol 54: 300-306, 2001.
7. Hedman H, Nilsson J, Guo D and Henriksson R: Is LRIG1 a tumour suppressor gene at chromosome 3p14. 3? Acta Oncol 41: 352-354, 2002.
8. Thomasson M, Hedman H, Guo D, Ljungberg B and Henriksson R: LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Br J Cancer 89: 1285-1289, 2003.
9. Yang WM, Yan ZJ, Ye ZQ and Guo DS: LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87. BJU Int 98: 898-902, 2006.
10. Tanemura A, Nagasawa T, Inui S and Itami S: LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423-430, 2005.
11. Gur G, Rubin C, Katz M, et al: LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23: 3270-3281, 2004.
12. Lindstrom AK, Ekman K, Stendahl U, et al: LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 18: 312-317, 2008.
13. Miller JK, Shattuck DL, Ingalla EQ, et al: Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 68: 8286-8294, 2008.
14. Li F, Ye ZQ, Guo DS and Yang WM: Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1. Oncol Rep 26: 439-446, 2011.
15. Welsh JB, Sapinoso LM, Su AI, et al: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61: 5974-5978, 2001.
16. Lapointe J, Li C, Higgins JP, et al: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811-816, 2004.
17. Hedman H and Henriksson R: LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer 43: 676-682, 2007.
18. Ye F, Gao Q, Xu T, et al: Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J Neurooncol 94: 183-194, 2009.
19. Guo D, Nilsson J, Haapasalo H, et al: Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 111: 238-246, 2006.
20. Yuan B, Latek R, Hossbach M, Tuschl T and Lewitter F: siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res 32: W130-W134, 2004.
21. Tuschl T: Expanding small RNA interference. Nat Biotechnol 20: 446-448, 2002.
22. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF and Valerie K: Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8: 730-738, 2009.
23. Rao SK, Edwards J, Joshi AD, Siu IM and Riggins GJ: A survey of glioblastoma genomic amplifications and deletions. J Neurooncol 96: 169-179, 2010.
24. Yeh KY, Chang JW, Li YY, Wang CH and Wang HM: Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis. Head Neck 33: 734-742, 2011.
25. Chandele A, Prasad V, Jagtap JC, Shukla R and Shastry PR: Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6: 29-40, 2004.
26. Tate MC and Aghi MK: Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6: 447-457, 2009.
27. Wild-Bode C, Weller M and Wick W: Molecular determinants of glioma cell migration and invasion. J Neurosurg 94: 978-984, 2001.
28. Rao JS: Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3: 489-501, 2003.
29. Kapoor GS and O'Rourke DM: Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches. Cancer Biol Ther 2: 330-342, 2003.
30. Fu Y, Zhang Q, Kang C, et al: Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. Cancer Biol Ther 8: 1002-1009, 2009.
31. Laederich MB, Funes-Duran M, Yen L, et al: The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050-47056, 2004.
32. Shindo H, Tani E, Matsumuto T, Hashimoto T and Furuyama J: Stabilization of c-myc protein in human glioma cells. Acta Neuropathol 86: 345-352, 1993.
33. Wang J, Wang H, Li Z, et al: c-Myc is required for maintenance of glioma cancer stem cells. PLoS One 3: e3769, 2008.
34. Jensen KB and Watt FM: Single-cell expression profiling of human epidermal stem and transit-amplifying cells: LRIG1 is a regulator of stem cell quiescence. Proc Natl Acad Sci USA 103: 11958-11963, 2006.
35. Dang CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1-11, 1999.